- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07262619
EIK1005-002: Uno Studio di Ricerca Clinica per Valutare EIK1005, un Inibitore dell'Elicasi di Werner, in Monoterapia e in Combinazione con Pembrolizumab in Partecipanti con Tumori Solidi Avanzati, Compresi i Tumori con Alta Instabilità dei Microsatelliti (MSI-H)
Uno studio multicentrico, in più parti, di Fase 1/2 su EIK1005 in monoterapia e in combinazione con pembrolizumab in partecipanti con tumori solidi avanzati, inclusi partecipanti naïve agli inibitori dei checkpoint con tumori ad alta instabilità dei microsatelliti (MSI-H) o con deficit di riparazione degli errori di appaiamento (dMMR)
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
This Phase 1/2 study (EIK1005-002) will investigate the safety and tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of EIK1005 as a monotherapy and in combination with pembrolizumab in participants with advanced solid tumors, including participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors.
The study will be conducted in 2 parts: Part 1 and Part 2, with Part 1 being further divided into Part 1A and Part 1B as described below:
- Part 1A (monotherapy dose escalation): participants will receive EIK1005 only.
- Part 1B (combination dose escalation): participants will receive EIK1005 in combination with pembrolizumab.
- Part 2 (dose optimization): participants will be randomized 1:1 to monotherapy with EIK1005 at one of the two selected doses from Part 1A to identify the dose of EIK1005 in monotherapy for subsequent studies.
Tipo di studio
Iscrizione (Stimato)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Contatto studio
- Nome: Ana C Mamede, PharmD
- Numero di telefono: 347-806-4584
- Email: mamedea@eikontx.com
Backup dei contatti dello studio
- Nome: Krishna Kaza
- Email: kazak@eikontx.com
Luoghi di studio
-
-
New South Wales
-
Saint Leonards, New South Wales, Australia
- Non ancora reclutamento
- GenesisCare North Shore (Oncology)
-
Waratah, New South Wales, Australia
- Reclutamento
- Calvary Mater Newcastle Hospital
-
-
Victoria
-
Ballarat, Victoria, Australia
- Reclutamento
- Grampians Health
-
Camperdown, Victoria, Australia
- Reclutamento
- Chris O'Brien Lifehouse (Sydney Cancer Centre)
-
Frankston, Victoria, Australia
- Reclutamento
- Peninsula and Southeast Oncology (PASO) Medical
-
Frankston, Victoria, Australia, 3199
- Reclutamento
- Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
-
-
-
-
-
Linz, Austria, 4020
- Reclutamento
- Ordensklinikum Linz Elisabethinen
-
-
-
-
-
Brussels, Belgio, 1020
- Reclutamento
- Centre Hospitalier Universitaire Brugmann - Victor Horta
-
-
-
-
-
Seoul, Corea del Sud, 02841
- Reclutamento
- Korea University Anam Hospital
-
Suwon, Corea del Sud, 16499
- Reclutamento
- Ajou University School of Medicine & Graduate School of Medicine
-
-
Busan
-
Busan, Busan, Corea del Sud, 48108
- Reclutamento
- Inje University-Haeundae Paik Hospital
-
-
-
-
-
Kuopio, Finlandia, 70210
- Reclutamento
- Kuopio University Hospital
-
-
-
-
Rhone
-
Pierre-Bénite, Rhone, Francia, 69310
- Reclutamento
- Hospices Civils De Lyon (hcl) -Centre Hospitalier Lyon-Sud
-
-
-
-
-
Berlin, Germania, 13125
- Reclutamento
- Helios Klinikum Berlin-Buch
-
Hamburg, Germania, 22297
- Reclutamento
- Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
-
-
Bavaria
-
Deggendorf, Bavaria, Germania, 94469
- Reclutamento
- DONAUISAR Klinikum
-
-
-
-
-
Rome, Italia, 00128
- Reclutamento
- Campus Bio-Medico di Rome University
-
-
-
-
-
Oslo, Norvegia, 0379
- Reclutamento
- Oslo University
-
-
-
-
-
Wellington, Nuova Zelanda
- Reclutamento
- Health New Zealand
-
-
Manawatu
-
Roslyn, Manawatu, Nuova Zelanda, 4414
- Reclutamento
- Palmerstone North Hospital
-
-
-
-
-
Krakow, Polonia, 31-864
- Reclutamento
- GCPMED Sp. z o.o., Centrum Medyczne iMed24
-
Lodz, Polonia, 90-338
- Reclutamento
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
-
-
West Pomeranian Voivodeship
-
Szczecin, West Pomeranian Voivodeship, Polonia, 70-419
- Reclutamento
- One Day Med
-
-
-
-
-
Lisbon, Portogallo, 1649-028
- Reclutamento
- Hospital de Santa Maria
-
Loures, Portogallo, 2674-514
- Reclutamento
- Unidade Local de Saúde (ULS) Loures Odivelas
-
Porto, Portogallo, 4200
- Reclutamento
- Instituto Português de Oncologia do Porto Francisco Gentil, E.P.E. (IPO Porto)
-
-
Lisbon District
-
Lisbon, Lisbon District, Portogallo, 1500-650
- Reclutamento
- Hospital da Luz Lisboa
-
-
-
-
-
Singapore, Singapore, 119074
- Reclutamento
- National University Hospital (NUH)
-
-
Central Region
-
Singapore, Central Region, Singapore, 168583
- Reclutamento
- National Cancer Centre Singapore (NCCS)
-
-
-
-
-
Barcelona, Spagna, 08023
- Reclutamento
- START - Barcelona
-
Logroño, Spagna, 26006
- Reclutamento
- START Rioja - Hospital de San Pedro
-
Madrid, Spagna, 28233
- Reclutamento
- NEXT Madrid HUQSM
-
Zaragoza, Spagna, 50009
- Reclutamento
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma, Balearic Islands, Spagna, 07120
- Reclutamento
- Hospital Universitari Son Espases
-
-
Barcelona
-
Barcelona, Barcelona, Spagna, 8036
- Reclutamento
- Hospital Clinic Barcelona
-
-
-
-
California
-
Los Angeles, California, Stati Uniti, 90027
- Reclutamento
- California Research Institute (CRI)
-
-
Florida
-
Doral, Florida, Stati Uniti, 33172
- Reclutamento
- Omnicure Clinical Research
-
Hialeah, Florida, Stati Uniti, 33013
- Reclutamento
- Bioresearch Partner
-
Plantation, Florida, Stati Uniti, 33322
- Reclutamento
- Florida Clinical Trials Group
-
Tamarac, Florida, Stati Uniti, 33321
- Reclutamento
- Florida Clinical Trials Group - Tamarac
-
-
New Jersey
-
Morristown, New Jersey, Stati Uniti, 07960
- Reclutamento
- Morristown Medical Center
-
-
New York
-
Lake Success, New York, Stati Uniti, 11042
- Reclutamento
- START New York-Long Island
-
New York, New York, Stati Uniti, 10022
- Reclutamento
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
-
Texas
-
Fort Worth, Texas, Stati Uniti, 76104
- Reclutamento
- START Dallas Fort Worth
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- University of Texas MD Anderson Cancer Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Key Inclusion Criteria:
- is ≥ 18 years of age at the time of signing the informed consent.
- has a life expectancy of at least 3 months.
- has histologically or cytologically documented advanced (unresectable and/or metastatic) solid tumor. Part 1A: recommend that participants have archival tissue not more than 3 years old. Part 1B and Part 2: participant has locally confirmed Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) tumor. Participant must have archival tumor tissue (not more than 3 years old) for retrospective confirmation of MSI-H or dMMR tumor by a central laboratory.
- In Part 1A, has received and then progressed after or is intolerant to at least 1 standard treatment regimen in the advanced setting. The participant does not have alternative therapeutic options per PI's medical judgement. Preference should be given to: (1) participants with MSI-H or dMMR cancers that have progressed after checkpoint inhibitor (CPI) therapy and (2) participants with microsatellite stable cells (MSS) cancers that have progressed following at least one regimen of platinum, alkylating or topoisomerase containing chemotherapy.
- has measurable disease at baseline according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as determined by the PI.
- has an Eastern Cooperative Oncology Group (ECOG) score of 0 to 1.
- has an adequate organ and marrow function.
Key Exclusion Criteria:
- has not recovered (i.e., to Grade ≤ 1 or to baseline) from prior anti-cancer therapy-induced adverse events (AEs).
- has received prior treatment with Werner (WRN) inhibitor.
- has a history of relevant drug hypersensitivity, ascertained or presumptive allergy/hypersensitivity to the active drug substance and/or formulation ingredients, history of serious allergic reactions leading to hospitalization, or any other allergic reaction in general.
- In Parts 1B and Part 2 Rescue: diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention.
- has known additional malignancy that is progressing or has required active treatment within the past 3 years.
- has known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks as confirmed by repeat imaging performed during the study screening, are clinically stable and have not required steroid treatment for at least 14 days before the first dose of study treatment.
- has mean resting QTcF > 470 ms (men and women) obtained from triplicate electrocardiograms (ECGs).
- has active autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids, or immunosuppressive drugs). Participants may enroll with the following conditions: Type 1 diabetes, hypothyroidism requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia not requiring systemic treatment).
- has history of (non-infectious) pneumonitis/pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease.
- has active tuberculosis.
- has any active infections requiring systemic therapy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione sequenziale
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Part 1A (Dose escalation, Monotherapy)
EIK1005 will be given as monotherapy in participants without alternative treatment options. |
EIK1005 is a selective inhibitor of the Werner helicase. |
|
Sperimentale: Part 1B (Dose escalation, Combination with pembrolizumab)
EIK1005 will be given in combination with pembrolizumab to participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) solid tumors. |
EIK1005 is a selective inhibitor of the Werner helicase. Pembrolizumab is a PD-1 inhibitor. |
|
Sperimentale: Part 2 (Dose optimization, Monotherapy)
Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) advanced solid tumors will be randomized to receive EIK1005 monotherapy at one of the two identified doses selected from Part 1A. |
EIK1005 is a selective inhibitor of the Werner helicase. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose-Limiting Toxicity (DLT) - Part 1
Lasso di tempo: 21 Days
|
A DLT is a protocol-defined adverse event occurring during the DLT observation period. |
21 Days
|
|
Adverse Events (AEs) - Part 1 and Part 2
Lasso di tempo: From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Number of participants reporting adverse events or serious adverse events. |
From the time of first dose of study medication through 30 days following cessation of study treatment.
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response (OR) - Part 1 and Part 2
Lasso di tempo: Through study completion, an average of 2 years.
|
OR defined as participants who have a complete response [CR] or partial response [PR] by Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Duration of Response (DOR) - Part 1 and Part 2
Lasso di tempo: Through study completion, an average of 2 years.
|
DOR (defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first, in participants demonstrating CR or PR) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Disease Control (DC) - Part 1 and Part 2
Lasso di tempo: Through study completion, an average of 2 years.
|
DC defined as participants with a best overall response (BOR) of complete response (CR), partial response (PR), or stable disease (SD) by RECIST 1.1 as assessed by the Investigator. |
Through study completion, an average of 2 years.
|
|
Progression-free survival (PFS) - Part 2
Lasso di tempo: Through study completion, an average of 2 years.
|
PFS defined as the time from randomization to the first documented disease progression by RECIST 1.1 as assessed by the Investigator or death due to any cause, whichever occurs first. |
Through study completion, an average of 2 years.
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUC0-24 (Part 1 and Part 2)
Lasso di tempo: Up to 1 year
|
AUC0-24 (Area Under the plasma Concentration versus time curve from 0 to 24 hours): Measures total drug exposure over the first 24 hours after dosing of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - AUCtau,ss (Part 1 and Part 2)
Lasso di tempo: Up to 1 year
|
AUCtau,ss [Area Under the plasma Concentration versus time curve over one dosing interval (tau) at steady state]: Reflects average drug exposure during each dosing interval once the steady state has been reached for EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - Cmax (Part 1 and Part 2)
Lasso di tempo: Up to 1 year
|
Cmax (Maximum Plasma Concentration) after dose administration of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - tmax (Part 1 and Part 2)
Lasso di tempo: Up to 1 year
|
tmax (the time required for the plasma concentration of the drug to reach maximum concentration after dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
|
Pharmacokinetic (PK) parameters of EIK1005 - t½ (Half-life) (Part 1 and Part 2)
Lasso di tempo: Up to 1 year
|
Half-life (the time required for the plasma concentration of the drug to decrease by 50% after the dose administration) of EIK1005 as monotherapy and in combination with pembrolizumab. |
Up to 1 year
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Direttore dello studio: Nilou Mobashery, MD, Eikon Therapeutics, Inc.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie urogenitali
- Malattie genitali
- Processi patologici
- Neoplasie urogenitali
- Neoplasie per sede
- Neoplasie
- Malattie urogenitali femminili
- Malattie urogenitali femminili e complicanze della gravidanza
- Malattie uterine
- Malattie genitali, femmina
- Processi neoplastici
- Neoplasie genitali, femmina
- Neoplasie uterine
- Condizioni patologiche, segni e sintomi
- Metastasi neoplastica
- Neoplasie endometriali
- Sindrome di Turcot
- pembrolizumab
Altri numeri di identificazione dello studio
- EIK1005-002
- 2026-525248-13-00 (Ctis)
- KEYNOTE-G56 (Altro identificatore: Merck Sharp & Dohme LLC)
- MK-3475-G56 (Altro identificatore: Merck Sharp & Dohme LLC)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .